IgA肾病治疗进展
Advances in the treatment of IgA nephropathy
徐媛 1邓芳1
作者信息
- 1. 安徽省儿童医院肾内科,合肥 230051
- 折叠
摘要
IgA肾病(IgAnephropathy,IgAN)是我国肾小球源性血尿最常见的病因,以反复发作性的肉眼血尿或镜下血尿、肾小球系膜区IgA沉积为主要特征,是目前世界范围内最常见的原发性肾小球疾病.IgAN早期症状较轻,起病隐匿,病情进展缓慢,最终约40％进展为终末期肾病.由于IgAN的发病机制尚不完全清楚,其临床和病理表现多样,缺乏特异有效的治疗方法,目前以支持治疗为主.该文从支持治疗、激素类药物、免疫抑制剂、抗疟药和新型生物制剂等方面阐述IgAN的治疗进展.
Abstract
IgA nephropathy(IgAN)is the most common cause of glomerular hematuria in China.It is the most common primary glomerular disease in the world,mainly characterized by recurrent gross hematuria or microscopic hematuria and IgA deposition in the mesangial region.The early symptoms of IgAN are mild and the onset is insidious,with slowly progress and eventually about 40％to end-stage renal disease.So far,the pathogenesis of IgAN is not fully understood and its clinical and pathological manifestations are diverse.At present,supportive treatment is the main treatment and there is a lack of specific and effective treatment.In this paper,the therapeutic progress of IgAN will be reviewed from the aspects of supportive therapy,hormone drugs,immunosuppressants,antimalarial drugs and novel biologics.
关键词
儿童/IgA肾病/支持治疗/靶向治疗Key words
Children/IgA nephropathy/Supportive treatment/Targeted therapy引用本文复制引用
基金项目
安徽省自然科学基金(210085MH262)
出版年
2024
NETL
NSTL
万方数据